Literature DB >> 18089962

Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?

Clifford Rubin1, Thomas D Nolin, Jonathan Himmelfarb.   

Abstract

PURPOSE OF REVIEW: Chronic kidney disease is now recognized as an independent risk factor for cardiovascular events, and cardiovascular disease is the major cause of mortality in patients with the disease. Recent studies have attempted to evaluate the utility of biomarkers for assessing cardiovascular risk in patients with chronic kidney disease. This review will summarize these studies and critically assess the utility of cardiovascular risk biomarkers for clinical practice. RECENT
FINDINGS: Traditional cardiovascular risk factors including dyslipidemia, hypertension, smoking and diabetes mellitus are highly prevalent in patients with chronic kidney disease. Although prediction models using traditional risk factors underestimate cardiovascular disease risk in these patients, nontraditional biomarkers (i.e. markers of inflammation, endothelial dysfunction, myocardial necrosis, and left ventricular remodeling) have been associated with increased cardiovascular event rates and mortality risk in populations with and without chronic kidney disease. Moreover, a high prevalence of biomarkers that are directly attributable to loss of kidney function is observed in patients with the disease.
SUMMARY: Recent studies suggest only limited utility of either single or multiple biomarkers of cardiovascular risk as prognostic tools in patients with and without chronic kidney disease. Novel approaches for biomarker development capturing augmented information through a systems biology approach are urgently needed to improve the usefulness of cardiovascular risk biomarkers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089962     DOI: 10.1097/MNH.0b013e3282f0b331

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  7 in total

Review 1.  Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.

Authors:  Uwe Christians; Jost Klawitter; Jelena Klawitter; Nina Brunner; Volker Schmitz
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-02       Impact factor: 4.481

2.  Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study.

Authors:  Mireia Junyent; Montserrat Martínez; Mercè Borràs; Blai Coll; Jose Manuel Valdivielso; Teresa Vidal; Felipe Sarró; Jordi Roig; Lourdes Craver; Elvira Fernández
Journal:  BMC Nephrol       Date:  2010-07-07       Impact factor: 2.388

3.  The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.

Authors:  Alper Sonmez; Mahmut Ilker Yilmaz; Mutlu Saglam; Hilmi Umut Unal; Mahmut Gok; Hakki Cetinkaya; Murat Karaman; Cem Haymana; Tayfun Eyileten; Yusuf Oguz; Abdulgaffar Vural; Manfredi Rizzo; Peter P Toth
Journal:  Lipids Health Dis       Date:  2015-04-16       Impact factor: 3.876

4.  The implications of aspirin resistance in renal failure.

Authors:  Jecko Thachil
Journal:  NDT Plus       Date:  2008-06

5.  Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.

Authors:  David Arroyo; Angels Betriu; Montserrat Martinez-Alonso; Teresa Vidal; Jose Manuel Valdivielso; Elvira Fernández
Journal:  BMC Nephrol       Date:  2014-10-18       Impact factor: 2.388

6.  Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients.

Authors:  Hao Shen; Yan Xu; Jingfen Lu; Chunfang Ma; Yadong Zhou; Qiong Li; Xu Chen; Ao Zhu; Guorong Shen
Journal:  BMC Nephrol       Date:  2016-10-06       Impact factor: 2.388

7.  Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study.

Authors:  Guido Filler; Sepideh Taheri; Christopher McIntyre; Connor Smith; Lakshmimathy Subramanian; Gerhard Fusch; Christoph Fusch
Journal:  Clin Kidney J       Date:  2017-10-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.